COMPASS Pathways plc (CMPS) Discusses Positive Phase III Results for COMP360 in Treatment-Resistant Depression Trials Transcript
Source: SeekingAlpha
2026-02-17 17:14:56 ET
COMPASS Pathways plc (CMPS) Discusses Positive Phase III Results for COMP360 in Treatment-Resistant Depression Trials February 17, 2026 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
COMPASS Pathways plc (CMPS) Discusses Positive Phase III Results for COMP360 in Treatment-Resistant Depression Trials Transcript
COMPASS Pathways Plc
NASDAQ: CMPS
CMPS Trading
-3.35% G/L:
$6.92 Last:
1,679,278 Volume:
$7.34 Open:
CMPS Latest News
February 26, 2026 12:07:00 pm
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
February 26, 2026 06:30:00 am
Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants
February 24, 2026 06:39:00 am
Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
CMPS Stock Data
$604,427,292
92,243,574
0.05%
52
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
